David M. Stout Joins NanoBio Corporation's Board of Directors

May 29, 2008, 01:00 ET from NanoBio Corporation

    ANN ARBOR, Mich., May 29 /PRNewswire/ -- NanoBio(R) Corporation, a
 biopharmaceutical company focused on developing and commercializing novel
 products for the prevention and treatment of infectious diseases, today
 announced the appointment of David M. Stout to its Board of Directors. Mr.
 Stout most recently served as President of Pharmaceutical Operations for
 GlaxoSmithKline Pharmaceuticals.
     "We are pleased to welcome David to our Board of Directors and look
 forward to benefiting from his guidance and contributions," said James R.
 Baker Jr., M.D., chairman of NanoBio Corporation. "David's 30-plus years of
 experience in all facets of the pharmaceutical industry -- including his
 recent experience as head of global pharmaceutical operations for GSK, a
 world leader in infectious diseases -- will be invaluable to NanoBio as we
 approach the commercialization of our lead anti-infective and vaccine
 product candidates."
     NanoBio's lead products are topical lotions and mucosal vaccines to
 combat a wide array of viruses, bacteria and fungi. They include topical
 treatments for herpes labialis (cold sores), onychomycosis (nail fungus)
 and bacterial skin infections (including MRSA), as well as mucosal vaccines
 for seasonal and pandemic influenza, hepatitis B and RSV. The company's
 nanoemulsion-based products have demonstrated potent antimicrobial effects
 in several clinical trials, without safety concerns or systemic absorption.
 The products use a physical mode of action rather than chemical synthesis
 to disrupt pathogen membranes, rendering the emergence of drug resistance
     "The platform technology upon which NanoBio's products are based
 represents a truly novel approach to combating infections and provides a
 rich pipeline of anti-infective products and vaccines for the future,"
 Stout said. "Given the company's recent and very compelling clinical
 results, I am particularly excited to be joining the company's board at
 this time. I look forward to working with NanoBio's management in bringing
 these new therapies and vaccines to the market."
     In his most recent position as President of Pharmaceutical Operations
 at GSK, Mr. Stout led all global commercial activities, global
 manufacturing and all vaccine-related activities, including research and
 development, as well as other executive functions. Additionally, Mr. Stout
 directed the corporate pandemic flu preparedness program, an international
 effort that supports governments, health authorities and company employees
 around the world in planning to respond to a global influenza pandemic.
 Prior to his tenure at GSK, Mr. Stout held executive leadership positions
 at Glaxo Wellcome, SmithKline Beecham and Schering-Plough Corporation.
     About NanoBio
     NanoBio(R) Corporation is a privately held biopharmaceutical company
 focused on developing and commercializing anti-infective products and
 mucosal vaccines derived from its patented NanoStat(TM) technology
 platform. The company's lead product candidates are treatments for herpes
 labialis (cold sores), onychomycosis (nail fungus) and mucosal vaccines for
 influenza and hepatitis B. The company's headquarters and laboratory
 facilities are located in Ann Arbor, Mich.

SOURCE NanoBio Corporation